Literature DB >> 21990408

Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: time to reflect again?

John M S Bartlett, Jane Starczynski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21990408     DOI： 10.1200/JCO.2011.37.5824

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system.

Authors:  S Martel; M Lambertini; R Simon; C Matte; C Prady
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

Review 2.  HER2-positive breast cancer is lost in translation: time for patient-centered research.

Authors:  Isabelle Gingras; Géraldine Gebhart; Evandro de Azambuja; Martine Piccart-Gebhart
Journal:  Nat Rev Clin Oncol       Date:  2017-08-01       Impact factor: 66.675

3.  The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

Authors:  Edith A Perez; Frederick L Baehner; Steven M Butler; E Aubrey Thompson; Amylou C Dueck; Farid Jamshidian; Diana Cherbavaz; Carl Yoshizawa; Steven Shak; Peter A Kaufman; Nancy E Davidson; Julie Gralow; Yan W Asmann; Karla V Ballman
Journal:  Breast Cancer Res       Date:  2015-10-01       Impact factor: 6.466

4.  The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.

Authors:  Elisabeth Hofmann; Rita Seeboeck; Nico Jacobi; Peter Obrist; Samuel Huter; Christian Klein; Kamil Oender; Christoph Wiesner; Harald Hundsberger; Andreas Eger
Journal:  Biomark Res       Date:  2016-04-07

5.  Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.

Authors:  Gabriele Zoppoli; Anna Garuti; Gabriella Cirmena; Ludovica Verdun di Cantogno; Cristina Botta; Maurizio Gallo; Domenico Ferraioli; Enrico Carminati; Paola Baccini; Monica Curto; Piero Fregatti; Edoardo Isnaldi; Michela Lia; Roberto Murialdo; Daniele Friedman; Anna Sapino; Alberto Ballestrero
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

6.  Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer.

Authors:  Hossein Ayatollahi; Azar Fani; Ehsan Ghayoor Karimiani; Fateme Homaee; Arezoo Shajiei; Maryam Sheikh; Sepideh Shakeri; Seyyede Fatemeh Shams
Journal:  Iran J Pathol       Date:  2017-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.